Extensive surface phenotyping of alveolar macrophages in interstitial lung disease

Marcia L. Taylor, Paul W. Noble, Barbara White, Robert A Wise, Mark Chang Hwa Liu, Bruce S. Bochner

Research output: Contribution to journalArticle

Abstract

There is increasing evidence implicating activated macrophages in the pathogenesis of interstitial and other lung diseases. We investigated whether there was a unique pattern of cell surface expression that constituted a disease-specific phenotype on alveolar macrophages from patients with interstitial lung disease (ILD). Macrophage cell surface receptor expression of 19 selected markers was assessed by indirect immunofluorescence and flow cytometry in bronchoalveolar lavage (BAL) fluids from patients with idiopathic pulmonary fibrosis (IPF, n = 4), scleroderma (SCL-ILD, n = 14), mild asthma (n = 7), allergy without asthma (n = 2), and normal subjects (n = 9). There was increased expression of adhesion receptors (CD11c, CD29, CD36, CD44, CD49e, CD54), receptors involved in signal transduction and/or inflammation (CD13, CD45, CD53), and other markers (CD9, CD52, CD71, CD98, HLA Class I) on macrophages from ILD patients compared to the non-ILD group. Most markers upregulated on macrophages in ILD were significantly inversely correlated with clinical parameters of disease activity such as FEV1, FVC, and DL(CO) and positively correlated with numbers of BAL neutrophils and eosinophils. Increased expression of several cell surface markers suggests that activated alveolar macrophages may contribute to the pathophysiology of IPF and SCL-ILD.

Original languageEnglish (US)
Pages (from-to)33-41
Number of pages9
JournalClinical Immunology
Volume94
Issue number1
DOIs
StatePublished - Jan 2000

Fingerprint

Interstitial Lung Diseases
Alveolar Macrophages
Macrophages
Asthma
Idiopathic Pulmonary Fibrosis
Bronchoalveolar Lavage Fluid
Cell Surface Receptors
Bronchoalveolar Lavage
Carbon Monoxide
Indirect Fluorescent Antibody Technique
Eosinophils
Lung Diseases
Signal Transduction
Flow Cytometry
Hypersensitivity
Neutrophils
Inflammation
Phenotype

Keywords

  • Alveolar macrophages
  • CD markers
  • Idiopathic pulmonary fibrosis
  • Interstitial lung disease
  • Phenotyping
  • Scleroderma

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Cite this

Extensive surface phenotyping of alveolar macrophages in interstitial lung disease. / Taylor, Marcia L.; Noble, Paul W.; White, Barbara; Wise, Robert A; Liu, Mark Chang Hwa; Bochner, Bruce S.

In: Clinical Immunology, Vol. 94, No. 1, 01.2000, p. 33-41.

Research output: Contribution to journalArticle

Taylor, Marcia L. ; Noble, Paul W. ; White, Barbara ; Wise, Robert A ; Liu, Mark Chang Hwa ; Bochner, Bruce S. / Extensive surface phenotyping of alveolar macrophages in interstitial lung disease. In: Clinical Immunology. 2000 ; Vol. 94, No. 1. pp. 33-41.
@article{63c0ee0b3d964e8db2412ae23bf2c58c,
title = "Extensive surface phenotyping of alveolar macrophages in interstitial lung disease",
abstract = "There is increasing evidence implicating activated macrophages in the pathogenesis of interstitial and other lung diseases. We investigated whether there was a unique pattern of cell surface expression that constituted a disease-specific phenotype on alveolar macrophages from patients with interstitial lung disease (ILD). Macrophage cell surface receptor expression of 19 selected markers was assessed by indirect immunofluorescence and flow cytometry in bronchoalveolar lavage (BAL) fluids from patients with idiopathic pulmonary fibrosis (IPF, n = 4), scleroderma (SCL-ILD, n = 14), mild asthma (n = 7), allergy without asthma (n = 2), and normal subjects (n = 9). There was increased expression of adhesion receptors (CD11c, CD29, CD36, CD44, CD49e, CD54), receptors involved in signal transduction and/or inflammation (CD13, CD45, CD53), and other markers (CD9, CD52, CD71, CD98, HLA Class I) on macrophages from ILD patients compared to the non-ILD group. Most markers upregulated on macrophages in ILD were significantly inversely correlated with clinical parameters of disease activity such as FEV1, FVC, and DL(CO) and positively correlated with numbers of BAL neutrophils and eosinophils. Increased expression of several cell surface markers suggests that activated alveolar macrophages may contribute to the pathophysiology of IPF and SCL-ILD.",
keywords = "Alveolar macrophages, CD markers, Idiopathic pulmonary fibrosis, Interstitial lung disease, Phenotyping, Scleroderma",
author = "Taylor, {Marcia L.} and Noble, {Paul W.} and Barbara White and Wise, {Robert A} and Liu, {Mark Chang Hwa} and Bochner, {Bruce S.}",
year = "2000",
month = "1",
doi = "10.1006/clim.1999.4803",
language = "English (US)",
volume = "94",
pages = "33--41",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Extensive surface phenotyping of alveolar macrophages in interstitial lung disease

AU - Taylor, Marcia L.

AU - Noble, Paul W.

AU - White, Barbara

AU - Wise, Robert A

AU - Liu, Mark Chang Hwa

AU - Bochner, Bruce S.

PY - 2000/1

Y1 - 2000/1

N2 - There is increasing evidence implicating activated macrophages in the pathogenesis of interstitial and other lung diseases. We investigated whether there was a unique pattern of cell surface expression that constituted a disease-specific phenotype on alveolar macrophages from patients with interstitial lung disease (ILD). Macrophage cell surface receptor expression of 19 selected markers was assessed by indirect immunofluorescence and flow cytometry in bronchoalveolar lavage (BAL) fluids from patients with idiopathic pulmonary fibrosis (IPF, n = 4), scleroderma (SCL-ILD, n = 14), mild asthma (n = 7), allergy without asthma (n = 2), and normal subjects (n = 9). There was increased expression of adhesion receptors (CD11c, CD29, CD36, CD44, CD49e, CD54), receptors involved in signal transduction and/or inflammation (CD13, CD45, CD53), and other markers (CD9, CD52, CD71, CD98, HLA Class I) on macrophages from ILD patients compared to the non-ILD group. Most markers upregulated on macrophages in ILD were significantly inversely correlated with clinical parameters of disease activity such as FEV1, FVC, and DL(CO) and positively correlated with numbers of BAL neutrophils and eosinophils. Increased expression of several cell surface markers suggests that activated alveolar macrophages may contribute to the pathophysiology of IPF and SCL-ILD.

AB - There is increasing evidence implicating activated macrophages in the pathogenesis of interstitial and other lung diseases. We investigated whether there was a unique pattern of cell surface expression that constituted a disease-specific phenotype on alveolar macrophages from patients with interstitial lung disease (ILD). Macrophage cell surface receptor expression of 19 selected markers was assessed by indirect immunofluorescence and flow cytometry in bronchoalveolar lavage (BAL) fluids from patients with idiopathic pulmonary fibrosis (IPF, n = 4), scleroderma (SCL-ILD, n = 14), mild asthma (n = 7), allergy without asthma (n = 2), and normal subjects (n = 9). There was increased expression of adhesion receptors (CD11c, CD29, CD36, CD44, CD49e, CD54), receptors involved in signal transduction and/or inflammation (CD13, CD45, CD53), and other markers (CD9, CD52, CD71, CD98, HLA Class I) on macrophages from ILD patients compared to the non-ILD group. Most markers upregulated on macrophages in ILD were significantly inversely correlated with clinical parameters of disease activity such as FEV1, FVC, and DL(CO) and positively correlated with numbers of BAL neutrophils and eosinophils. Increased expression of several cell surface markers suggests that activated alveolar macrophages may contribute to the pathophysiology of IPF and SCL-ILD.

KW - Alveolar macrophages

KW - CD markers

KW - Idiopathic pulmonary fibrosis

KW - Interstitial lung disease

KW - Phenotyping

KW - Scleroderma

UR - http://www.scopus.com/inward/record.url?scp=0033982301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033982301&partnerID=8YFLogxK

U2 - 10.1006/clim.1999.4803

DO - 10.1006/clim.1999.4803

M3 - Article

VL - 94

SP - 33

EP - 41

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 1

ER -